From Yahoo Finance: 2025-06-02 08:59:00

Indivior, a drugmaker, has abandoned its London listing, citing better liquidity and shareholder location in the US. The move reflects its focus on the US market, where most shareholders are based. The London Stock Exchange faces pressure to attract new companies after losing 88 listings last year.

Indivior, known for opioid addiction treatments, posted $1.2bn in sales last year. Its business focuses on the US, where most of its shareholders reside. The company will discontinue its schizophrenia drug Perseris, and faces lawsuits over its Suboxone film’s design and marketing practices.

Indivior’s former parent, Reckitt, paid a $1.4bn fine in 2019 over opioid sales. Indivior pleaded guilty to making a false statement in 2012 and agreed to pay $600m over seven years. The former CEO, Shaun Thaxter, was sentenced to six months in prison for misleading officials about Suboxone film’s dangers.

The exodus of companies from the London Stock Exchange continues, with Indivior being the latest to abandon its listing. The LSE faces pressure to attract new listings and retain existing ones as companies opt for sole listings elsewhere, such as Frankfurt. The market lost 88 listings last year, the most since 2009.

Read more: Drugmaker Indivior to abandon London listing amid exodus of companies